# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

October 31, 2022 (Date of earliest event reported)

### LABORATORY CORPORATION OF AMERICA HOLDINGS

	(Exact 1	Name of Registrant as Specified in its Charte	er)
Delaware		1-11353	13-3757370
(State or o	other jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
	358 South Main Street		
Bur	lington, North Ca	arolina	27215
	(Address of principal executive offices)		(Zip Code)
	(Registrant's t	elephone number including area code) 336-2	229-1127
Check the appro following provisi		g is intended to simultaneously satisfy the	filing obligation of the registrant under any of the
<ul><li>□ Soliciting n</li><li>□ Pre-comme</li></ul>	•		* **
Securities registe	ered pursuant to Section 12(b) of the Exch	ange Act.	
<b>Title of Each Cl</b> e Common Stock,	3 î	of exchange on which registered rk Stock Exchange	
	12b-2 of the Securities Exchange Act of 1		of the Securities Act of 1933 (§230.405 of this
		the registrant has elected not to use the extent to Section 13(a) of the Exchange Act. $\Box$	nded transition period for complying with any new
Item 7.01	Regulation FD Disclosure		
fireside chat at th	ne Credit Suisse 31st Annual Healthcare C	any, today announced that members of the extended on Tuesday, Nov. 8, at 1:25 p.m. I Labcorp Investor Relations website and arc	
Item 9.01	Financial Statements and Exhibits		
<u>Exhibit</u> Exhibit 99.1	Exhibit Name Press Release dated October 31, 202	2 issued by Labcorp	

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

# <u>LABORATORY CORPORATION OF AMERICA HOLDINGS</u> Registrant

By: /s/ SANDRA VAN DER VAART

Sandra van der Vaart

Executive Vice President, Chief Legal Officer and Corporate Secretary

October 31, 2022



#### **FOR IMMEDIATE RELEASE**

**LabCorp Contacts:** 

Investors: Chas Cook — 336-436-5076

Investor@Labcorp.com

Media: Rachael Valdez - 336-436-8263

Media@Labcorp.com

## LABCORP TO SPEAK AT THE CREDIT SUISSE 31ST ANNUAL HEALTHCARE CONFERENCE

**BURLINGTON, N.C., Oct. 31, 2022** — Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on Tuesday, Nov. 8, at 1:25 p.m PT.

A live webcast of the fireside chat will be available via the Labcorp Investor Relations website and archived for replay.

#### **About Labcorp**

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of \$16 billion in 2021. Learn more about us at <a href="https://www.labcorp.com">www.labcorp.com</a> or follow us on <a href="https://www.labcorp.com">LinkedIn</a> and Twitter @Labcorp.